Li Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Li Li has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Jianqing Hao
School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, China
6 shared publicationsJing Xu
School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, China
6 shared publicationsXiaohua Cui
School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, China
6 shared publicationsJinjuan Wang
School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, China
5 shared publicationsKai Yang
School of Basic Medical Sciences, Shanxi Medical University, Taiyuan, China
5 shared publications- Jianbing Liu
Departments of Obstetrics and Gynecology, Second Hospital of Shanxi Medical University, Taiyuan, China
4 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Overexpression of FEN1 promotes cervical cancer progression via upregulating PCNA expression
- 31 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessOverexpression of FEN1 promotes cervical cancer progression via upregulating PCNA expression
- 28 May 2026
- Published by Springer Nature in Human Cell
- Vol. 39 (6)
miR-141-5p positively regulates ACVRL1 expression to promote cervical cancer progression
Global cancer data show a continuous rise in cervical cancer incidence and mortality, burdening public health. To effectively mitigate this challenge, elucidating molecular pathogenesis and novel drug targets are critical for advancing clinical care. In this study, abnormally expressed miRNAs in cervical cancer were identified through TCGA data analysis. Expression levels were quantified using qRT-PCR and Western Blot, at both mRNA and protein levels, respectively. miR-141-5p and ACVRL1's interaction was validated with dual-luciferase assays. Cell behavior was evaluated using assays including CCK-8 assay. In vivo tumor growth was assessed in nude mice xenograft model. Database screening and subsequent validation using cancer cell lines and clinical samples revealed aberrantly elevated expression of miR-141-5p in cervical cancer. High expression of miR-141-5p in SiHa/HeLa cells significantly promoted cellular proliferation, migration, and invasion while concurrently inhibiting apoptosis, whereas its downregulation elicited opposing effects. ACVRL1 was identified as a direct target of miR-141-5p. Overexpressing miR-141-5p markedly upregulated ACVRL1 mRNA and protein levels, while its knockdown significantly reduced ACVRL1 expression at both mRNA and protein levels. Further functional analysis showed that ACVRL1 knockdown significantly impaired cellular proliferation, migration, and invasion while enhancing apoptosis in cervical cancer cells. Rescue experiments confirmed that miR-141-5p exerted regulatory effects on these cellular behaviors, at least partially through ACVRL1. miR-141-5p downregulation significantly suppressed tumor growth in vivo, as evidenced by reduced tumor volume and weight in nude mice. In brief, this study shows that miR-141-5p upregulation in cervical cancer promotes tumor progression via ACVRL1 regulation, indicating its potential in precision oncology.
- 28 May 2026
- Published by Springer Nature in Human Cell
- Vol. 39 (6)
miR-141-5p positively regulates ACVRL1 expression to promote cervical cancer progression
Global cancer data show a continuous rise in cervical cancer incidence and mortality, burdening public health. To effectively mitigate this challenge, elucidating molecular pathogenesis and novel drug targets are critical for advancing clinical care. In this study, abnormally expressed miRNAs in cervical cancer were identified through TCGA data analysis. Expression levels were quantified using qRT-PCR and Western Blot, at both mRNA and protein levels, respectively. miR-141-5p and ACVRL1's interaction was validated with dual-luciferase assays. Cell behavior was evaluated using assays including CCK-8 assay. In vivo tumor growth was assessed in nude mice xenograft model. Database screening and subsequent validation using cancer cell lines and clinical samples revealed aberrantly elevated expression of miR-141-5p in cervical cancer. High expression of miR-141-5p in SiHa/HeLa cells significantly promoted cellular proliferation, migration, and invasion while concurrently inhibiting apoptosis, whereas its downregulation elicited opposing effects. ACVRL1 was identified as a direct target of miR-141-5p. Overexpressing miR-141-5p markedly upregulated ACVRL1 mRNA and protein levels, while its knockdown significantly reduced ACVRL1 expression at both mRNA and protein levels. Further functional analysis showed that ACVRL1 knockdown significantly impaired cellular proliferation, migration, and invasion while enhancing apoptosis in cervical cancer cells. Rescue experiments confirmed that miR-141-5p exerted regulatory effects on these cellular behaviors, at least partially through ACVRL1. miR-141-5p downregulation significantly suppressed tumor growth in vivo, as evidenced by reduced tumor volume and weight in nude mice. In brief, this study shows that miR-141-5p upregulation in cervical cancer promotes tumor progression via ACVRL1 regulation, indicating its potential in precision oncology.
- Open Access
- 26 February 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (3)
Crosstalk between SPP1 + macrophages and ITGA5 + fibroblasts promotes hepatocellular carcinoma metastasis
Background: Hepatocellular carcinoma (HCC) develops from chronic inflammatory conditions to malignancy, with the immune microenvironment playing a significant role in this progression. However, the changes in the dynamic immune microenvironment during the transition from hepatitis to HCC remain poorly understood. Systematic analysis of stage-specific immune microenvironment alterations is essential for identifying therapeutic targets and creating precision strategies for HCC. Methods: Using single-cell RNA sequencing (scRNA-seq), we created dynamic transcriptome maps of the immune microenvironment across healthy liver, hepatitis, cirrhosis, and HCC stages. Cell–cell communication, trajectory, and enrichment analyses were utilized to characterize relationships between clusters. TCGA-LIHC data were used to validate gene expression and its prognosis. The spatial distribution of ligand–receptor complexes in HCC was confirmed by spatial transcriptomics and multiplexed immunofluorescence. The effects of the tumor microenvironment on cancer cell behavior were examined using co-immunoprecipitation and cell co-culture assays. Finally, the impact of the immune microenvironment on in vivo tumor progression was evaluated using a mouse transplantation model. Results: We identified specific immune cell clusters across HCC progression and revealed significant correlations between the abundance of immune cells (macrophages, B cells)and fibroblasts with disease severity. Crosstalk between SPP1 + macrophages and ITGA5 + fibroblasts was observed explicitly in HCC. In vitro and in vivo data demonstrated that the SPP1-ITGA5 interaction triggered the secretion of MMP2 by fibroblasts, thereby promoting malignant progression in HCC. Conclusions: We present a dynamic transcriptional profile of immune microenvironment evolution during HCC development, aiding in the refinement of diagnostics and the optimization of therapy strategies.
- 26 February 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (3)
Open AccessCrosstalk between SPP1 + macrophages and ITGA5 + fibroblasts promotes hepatocellular carcinoma metastasis
Background: Hepatocellular carcinoma (HCC) develops from chronic inflammatory conditions to malignancy, with the immune microenvironment playing a significant role in this progression. However, the changes in the dynamic immune microenvironment during the transition from hepatitis to HCC remain poorly understood. Systematic analysis of stage-specific immune microenvironment alterations is essential for identifying therapeutic targets and creating precision strategies for HCC. Methods: Using single-cell RNA sequencing (scRNA-seq), we created dynamic transcriptome maps of the immune microenvironment across healthy liver, hepatitis, cirrhosis, and HCC stages. Cell–cell communication, trajectory, and enrichment analyses were utilized to characterize relationships between clusters. TCGA-LIHC data were used to validate gene expression and its prognosis. The spatial distribution of ligand–receptor complexes in HCC was confirmed by spatial transcriptomics and multiplexed immunofluorescence. The effects of the tumor microenvironment on cancer cell behavior were examined using co-immunoprecipitation and cell co-culture assays. Finally, the impact of the immune microenvironment on in vivo tumor progression was evaluated using a mouse transplantation model. Results: We identified specific immune cell clusters across HCC progression and revealed significant correlations between the abundance of immune cells (macrophages, B cells)and fibroblasts with disease severity. Crosstalk between SPP1 + macrophages and ITGA5 + fibroblasts was observed explicitly in HCC. In vitro and in vivo data demonstrated that the SPP1-ITGA5 interaction triggered the secretion of MMP2 by fibroblasts, thereby promoting malignant progression in HCC. Conclusions: We present a dynamic transcriptional profile of immune microenvironment evolution during HCC development, aiding in the refinement of diagnostics and the optimization of therapy strategies.
- Open Access
- 22 July 2025
- Published by Springer Nature in Human Cell
- Vol. 38 (5) , 1-2
Correction: IL-32/NFκB/miR-205 loop sustains the high expression of IL-32 and enhances the motility of cervical cancer cells
- 22 July 2025
- Published by Springer Nature in Human Cell
- Vol. 38 (5) , 1-2
Open AccessCorrection: IL-32/NFκB/miR-205 loop sustains the high expression of IL-32 and enhances the motility of cervical cancer cells
- Open Access
- 19 March 2025
- Published by Elsevier in Translational Oncology
- Vol. 55, 102355
Tubeimoside I induces mitophagy by activating the PINK1/Parkin/Mfn2 signaling pathway in acute myeloid leukemia cells
- 19 March 2025
- Published by Elsevier in Translational Oncology
- Vol. 55, 102355
Open AccessTubeimoside I induces mitophagy by activating the PINK1/Parkin/Mfn2 signaling pathway in acute myeloid leukemia cells
- Open Access
- 28 August 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (10) , 107729
Overexpression of RBM4 promotes acute myeloid leukemia cell differentiation by regulating alternative splicing of TFEB
- 28 August 2024
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 300 (10) , 107729
Open AccessOverexpression of RBM4 promotes acute myeloid leukemia cell differentiation by regulating alternative splicing of TFEB
- 20 June 2024
- Published by Springer Nature in Human Cell
- Vol. 37 (5) , 1434-1445
IL-32/NFκB/miR-205 loop sustains the high expression of IL-32 and enhances the motility of cervical cancer cells
Human papillomavirus (HPV) infection is a major contributor to cervical cancer. Persistent HPV infection can trigger the expression of IL-32, yet the precise role of IL-32 in the occurrence and development of cervical cancer remains elusive. To investigate this, qRT‒PCR and western blotting were utilized to measure the mRNA and protein expression levels; bioinformatics analysis was used to screen differentially expressed miRNAs; wound healing and transwell assays were conducted to evaluate cell migration and invasion capabilities. Comparative analysis revealed significantly elevated IL-32 expression in cervical cancer tissues and cell lines compared to control groups. In SiHa and/or HeLa, overexpression of IL-32 and IL-32 exposure markedly upregulated miR-205, whereas its knockdown resulted in a substantial downregulation of miR-205. Furthermore, miR-205 also could significantly regulate the expression of IL-32 in HeLa and SiHa cells. Upregulation and downregulation of IL-32 led to a significant increase or decrease in NFκB expression, respectively. Treatment with BAY11-7082 (an NFκB inhibitor) notably decreased miR-205 expression but had no effect on IL-32 levels. qRT‒PCR and western blotting analyses demonstrated that both overexpression and underexpression of IL-32 and miR-205 significantly enhanced or reduced MMP2 and MMP9 expression in cervical cancer cells, respectively. Knockdown of IL-32 significantly inhibited the migration and invasion of HeLa and SiHa; conversely, treatment with rIL-32α and rIL-32γ notably promoted their migration and invasion. In brief, IL-32 is highly expressed via the formation of a positive regulatory loop with NFκB/miR-205, contributing to the persistence of inflammation and promoting the progression of cervical cancer.
- 20 June 2024
- Published by Springer Nature in Human Cell
- Vol. 37 (5) , 1434-1445
IL-32/NFκB/miR-205 loop sustains the high expression of IL-32 and enhances the motility of cervical cancer cells
Human papillomavirus (HPV) infection is a major contributor to cervical cancer. Persistent HPV infection can trigger the expression of IL-32, yet the precise role of IL-32 in the occurrence and development of cervical cancer remains elusive. To investigate this, qRT‒PCR and western blotting were utilized to measure the mRNA and protein expression levels; bioinformatics analysis was used to screen differentially expressed miRNAs; wound healing and transwell assays were conducted to evaluate cell migration and invasion capabilities. Comparative analysis revealed significantly elevated IL-32 expression in cervical cancer tissues and cell lines compared to control groups. In SiHa and/or HeLa, overexpression of IL-32 and IL-32 exposure markedly upregulated miR-205, whereas its knockdown resulted in a substantial downregulation of miR-205. Furthermore, miR-205 also could significantly regulate the expression of IL-32 in HeLa and SiHa cells. Upregulation and downregulation of IL-32 led to a significant increase or decrease in NFκB expression, respectively. Treatment with BAY11-7082 (an NFκB inhibitor) notably decreased miR-205 expression but had no effect on IL-32 levels. qRT‒PCR and western blotting analyses demonstrated that both overexpression and underexpression of IL-32 and miR-205 significantly enhanced or reduced MMP2 and MMP9 expression in cervical cancer cells, respectively. Knockdown of IL-32 significantly inhibited the migration and invasion of HeLa and SiHa; conversely, treatment with rIL-32α and rIL-32γ notably promoted their migration and invasion. In brief, IL-32 is highly expressed via the formation of a positive regulatory loop with NFκB/miR-205, contributing to the persistence of inflammation and promoting the progression of cervical cancer.
- 12 June 2024
- Published by S. Karger AG in Chemotherapy
- Vol. 69 (4) , 224-236
The Study of SRSF1 Regulates Abnormal Alternative Splicing of BCL2L11 and the Role in Refractory Acute Myeloid Leukemia
Introduction: Abnormalities in splicing factors, such as mutations or deregulated expression, can lead to aberrant splicing of target genes, potentially contributing to the pathogenesis of acute myeloid leukemia (AML). Despite this, the precise mechanism underlying the abnormal alternative splicing (AS) induced by SRSF1, a splicing factor associated with poor AML prognosis, remains elusive. Methods: Using strict splicing criteria, we globally screened for AS events in NPMc-positive and NPMc-negative AML samples from TCGA. An AS network associated with AML prognosis was then established. Functional assays, including CCK-8, flow cytometry, and Western blot, were conducted on K562 and THP-1 cells overexpressing SRSF1. Cell viability following 72-h Omipalisib treatment was also assessed. To explore the mechanism of SRSF1-induced AS, we created a BCL2L11 miniGene with a site-specific mutation at its branch point. The AS patterns of both wild-type and mutant miniGenes were analyzed following SRSF1 overexpression in HEK-293T, along with the subcellular localization of different spliceosomes. Results: SRSF1 was significantly associated with AML prognosis. Notably, its expression was markedly upregulated in refractory AML patients compared to those with a favorable chemotherapy response. Overexpression of SRSF1 promoted THP-1 cell proliferation, suppressed apoptosis, and reduced sensitivity to Omipalisib. Mechanistically, SRSF1 recognized an aberrant branch point within the BCL2L11 intron, promoting the inclusion of a cryptic exon 3, which in turn led to apoptosis arrest. Conclusion: Overexpression of SRSF1 and the resulting abnormal splicing of BCL2L11 are associated with drug resistance and poor prognosis in AML.
- 12 June 2024
- Published by S. Karger AG in Chemotherapy
- Vol. 69 (4) , 224-236
The Study of SRSF1 Regulates Abnormal Alternative Splicing of BCL2L11 and the Role in Refractory Acute Myeloid Leukemia
Introduction: Abnormalities in splicing factors, such as mutations or deregulated expression, can lead to aberrant splicing of target genes, potentially contributing to the pathogenesis of acute myeloid leukemia (AML). Despite this, the precise mechanism underlying the abnormal alternative splicing (AS) induced by SRSF1, a splicing factor associated with poor AML prognosis, remains elusive. Methods: Using strict splicing criteria, we globally screened for AS events in NPMc-positive and NPMc-negative AML samples from TCGA. An AS network associated with AML prognosis was then established. Functional assays, including CCK-8, flow cytometry, and Western blot, were conducted on K562 and THP-1 cells overexpressing SRSF1. Cell viability following 72-h Omipalisib treatment was also assessed. To explore the mechanism of SRSF1-induced AS, we created a BCL2L11 miniGene with a site-specific mutation at its branch point. The AS patterns of both wild-type and mutant miniGenes were analyzed following SRSF1 overexpression in HEK-293T, along with the subcellular localization of different spliceosomes. Results: SRSF1 was significantly associated with AML prognosis. Notably, its expression was markedly upregulated in refractory AML patients compared to those with a favorable chemotherapy response. Overexpression of SRSF1 promoted THP-1 cell proliferation, suppressed apoptosis, and reduced sensitivity to Omipalisib. Mechanistically, SRSF1 recognized an aberrant branch point within the BCL2L11 intron, promoting the inclusion of a cryptic exon 3, which in turn led to apoptosis arrest. Conclusion: Overexpression of SRSF1 and the resulting abnormal splicing of BCL2L11 are associated with drug resistance and poor prognosis in AML.